[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368236-105":59,"doc-detail-368236-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","six-events-that-shaped-antibody-approvals-in-oncology-perspective","Six events that shaped antibody approvals in oncology - Perspective","","Perspective analyzing six landmark regulatory and scientific milestones that transformed therapeutic antibody approvals in oncology from the rituximab era to the recent surge of antibody-drug conjugates and bispecific antibodies. The piece revisits the circumstances behind early approvals for rituximab and trastuzumab, explains how ADC and BsAb formats enabled more precise antibody-mediated cytotoxicity, and traces immune checkpoint inhibitor emergence. It also discusses cross-cancer checkpoint use enabled by genetic marker discoveries, providing critical insights for antibody-development processes.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/six-events-that-shaped-antibody-approvals-in-oncology-perspective/368236/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/six-events-that-shaped-antibody-approvals-in-oncology-perspective/368236.png","ImageObject",300,407,{"name":92,"@type":93},"Aria","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Which early antibodies does the article highlight and why are they important?","Question",{"text":112,"@type":113},"The article examines the approval circumstances of rituximab and trastuzumab as the first successful antibodies for treating hematologic and solid cancers, which helped reshape anti-cancer drug development.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What developments expanded precision and effectiveness of antibody therapies?",{"text":117,"@type":113},"It details how the generation of antibody-drug conjugate (ADC) and bispecific antibody (BsAb) formats dramatically augmented antibody-mediated precision cytotoxicity.",{"name":119,"@type":110,"acceptedAnswer":120},"How did immune checkpoint inhibitors become applicable across cancer types?",{"text":121,"@type":113},"The article discusses the development of ipilimumab as an early immune checkpoint-inhibiting antibody and explains that genetic markers enabled checkpoint inhibitors to be used across all cancer types.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},368236,1790483550,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},2336464648322,"https://ap-avatar.wpscdn.com/avatar/2200025388227c56fec?_k=1778556882303663488","TYPE Perspective  \nPUBLISHED 10 February 2025  \nDOI 10.3389/fimmu.2025.1533796  \nOPEN ACCESS  \nEDITED BY  \nGaurisankar Sa,  \nBose Institute, India  \nREVIEWED BY  \nSilvia Crescioli,  \nIndependent Researcher, London, United Kingdom  \nPalash Mandal,  \nCharotar University of Science and Technology, India  \n*CORRESPONDENCE  \nSuman Paul  \n [spaul19@jhmi.edu](spaul19@jhmi.edu)[ ](spaul19@jhmi.edu)Shibin Zhou  \n [sbzhou@jhmi.edu](sbzhou@jhmi.edu)  \nRECEIVED 24 November 2024  \nACCEPTED 20 January 2025  \nPUBLISHED 10 February 2025  \nCITATION  \nPaul S and Zhou S (2025) Six events that shaped antibody approvals in oncology. Front. Immunol. 16:1533796 .  \ndoi: 10.3389/fimmu.2025.1533796  \nCOPYRIGHT  \n© 2025 Paul and Zhou. This is an open-access article distributed under the terms of the  \nCreative Commons Attribution License (CC BY) .  \nThe use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nSix events that shaped antibody approvals in oncology  \nSuman Paul 1,2* and Shibin Zhou 1,2*  \n1 Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD, United States, 2 Ludwig Center for Cancer Genetics and Therapeutics, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD, United States  \nA little over twenty-ﬁve years ago, the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) approved the chimeric antibody rituximab which fundamentally altered the landscape of anti-cancer drugs. While only a few antibodies were approved in the immediate years that followed the rituximab approval, the last decade saw a wave of antibody-drug approvals in the oncology arena. In the last three years, the EMA and FDA greenlighted eighteen antibodies, the majority of them designed in the formats of antibody-drug conjugates (ADC) and bispeciﬁc antibodies (BsAb) . While the use of ADC and BsAb formats and the current rapid pace of approvals appear routine and almost inevitable, such progress was thought to be quite improbable in the early days of therapeutic antibody development. To understand how we arrived at the current state of antibody development in oncology, we focus on six monumental events that shaped antibody approvals over the last two and half decades. We examine the circumstances that led to the approval of rituximab and trastuzumab, the ﬁrst successful antibodies for the treatment of hematologic and solid cancers. We detail the generation of the ADC and BsAb formats that dramatically augmented antibody-mediated precision cytotoxicity. Finally, we explore the development of ipilimumab, the ﬁrst immune checkpoint-inhibiting antibody that activates the immune system to kill cancer cells, and the discovery that allowed the use of checkpoint inhibitors across all cancer types based on the presence of genetic markers. Revisiting these key events provides critical insights into the process of antibody development in oncology.  \nKEYWORDS  \nantibody, oncology, bispeciﬁc antibody (bsAb), antibody drug conjugate (ADC), immune checkpoint inhibitor  \nMain  \nOncology now has the largest share of prescription drugs with steadily increasing revenues over the last decade (1) . The explosive growth of cancer-targeting antibody drugs is due to a large patient population with signiﬁcant unmet medical needs and ongoing innovations in antibody design led by academic laboratories and pharmaceutical  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \ncompanies. Antibody development in oncology driven by collaborative work from academia and industry has surpassed the growth of other cancer-targeting agents such as kinase inhibitors, hormonal drugs, cancer vaccines, and chemotherapies by a wide margin","cbCaiu70iSyVvS4U","https://ap.wps.com/l/cbCaiu70iSyVvS4U","pdf",620088,"English","# Six events that shaped antibody approvals in oncology\n## Rituximab, the first successful antibody for cancer therapy\n## Key regulatory and scientific milestones","[{\"question\":\"Which early antibodies does the article highlight and why are they important?\",\"answer\":\"The article examines the approval circumstances of rituximab and trastuzumab as the first successful antibodies for treating hematologic and solid cancers, which helped reshape anti-cancer drug development.\"},{\"question\":\"What developments expanded precision and effectiveness of antibody therapies?\",\"answer\":\"It details how the generation of antibody-drug conjugate (ADC) and bispecific antibody (BsAb) formats dramatically augmented antibody-mediated precision cytotoxicity.\"},{\"question\":\"How did immune checkpoint inhibitors become applicable across cancer types?\",\"answer\":\"The article discusses the development of ipilimumab as an early immune checkpoint-inhibiting antibody and explains that genetic markers enabled checkpoint inhibitors to be used across all cancer types.\"}]","Six events that shaped antibody approvals in oncology - Perspective | PDF",1790175807,25,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c8a7a16bc742f43912e63142cafcec55.webp",983,1389,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bbff3ca142da16a982a8371aa6184ac8.webp",982,1388,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f8f285f55969eea04f41ef379a669458.webp",981,1386,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1ecd766c7b1bdf01a4e0118454e72e68.webp",980,1385]